A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland. (2025). Swiss Medical Weekly, 155(1), 3777. https://doi.org/10.57187/s.3777